Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Suspected pancreatic ductal adenocarcinoma. |
| |
| 2 | Chronic pancreatitis and slated for decompression treatment. |
| |
| 3 | Autoimmune pancreatitis. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mayo Interactive Breath Hold Monitor | Device | Biofeedback device |
|
| Measure | Description | Time Frame |
|---|---|---|
| A reproducible technique to measure CT perfusion parameters may provide a method for non-invasively monitoring tumor response during treatment, or differentiating between autoimmune and chronic pancreatitis. | Three weeks to three months for chronic pancreatitis. |
Not provided
Not provided
Inclusion Criteria:
2b. To undergo endoscopic or surgical decompression with 0 to 10 days of first study visit CT perfusion scan.
2c. To answer pain questionnaire before first CT perfusion scan.
2d. To return within three weeks to three months after decompression treatment for another CT perfusion scan and complete the second pain questionnaire.
3a. Autoimmune pancreatitis, age 18 to 99 years either with diffuse or focal swelling of the pancreas confirmed by CT, MRI, or EUS or
3b. Irregular narrowing of the pancreatic duct on ERCP and either elevated serum immunoglobulin G4 (IgG4), or histological confirmation.
Exclusion Criteria:
1a. Pancreatic ductal adenocarcinoma tumors with vascular involvement but without vascular occlusion.
Any Cohort:
4. Pregnant.
5. Prior iodine contrast reactions.
6. Iodine allergy.
7. Decreased kidney function being a serum creatinine greater than 1.5mg/dl.
8. Any contraindication to having a CT scan with iodine contrast.
Not provided
Not provided
Not provided
Mayo Clinic patients being seen in Pancreas Clinic.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Naoki Takahashi, M.D. | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | United States |
Not provided
| ID | Term |
|---|---|
| D050500 | Pancreatitis, Chronic |
| D000081012 | Autoimmune Pancreatitis |
| D007249 | Inflammation |
| D019512 | Pancreatitis, Alcoholic |
| D021441 | Carcinoma, Pancreatic Ductal |
| D010190 | Pancreatic Neoplasms |
| ID | Term |
|---|---|
| D010195 | Pancreatitis |
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D020751 | Alcohol-Induced Disorders |
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D044584 | Carcinoma, Ductal |
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D018299 | Neoplasms, Ductal, Lobular, and Medullary |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004701 | Endocrine Gland Neoplasms |
| D004700 | Endocrine System Diseases |